利奈唑胺对台湾地区10余年间分离的结核分枝杆菌复合群临床分离株的体外活性。
In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years.
作者信息
Huang Tsi-Shu, Liu Yung-Ching, Sy Cheng-Len, Chen Yao-Shen, Tu Hui-Zin, Chen Bao-Chen
机构信息
Section of Microbiology, Dept. of Pathology and Laboratory Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
出版信息
Antimicrob Agents Chemother. 2008 Jun;52(6):2226-7. doi: 10.1128/AAC.00414-07. Epub 2008 Apr 7.
Abstract
Significant increases in the MIC(90)s of linezolid in multidrug-resistant Mycobacterium tuberculosis isolates were seen between the baseline period of 2001 to 2003 (0.5 microg/ml) and 2004 (2 microg/ml). The MICs were 4 microg/ml in three strains. Both fluoroquinolones (except levofloxacin) and kanamycin were found to have statistically significant degrees of concordance with linezolid.
摘要
在2001年至2003年的基线期（最低抑菌浓度[MIC（90）]为0.5微克/毫升）和2004年（最低抑菌浓度为2微克/毫升）之间，耐多药结核分枝杆菌分离株对利奈唑胺的最低抑菌浓度（MIC[90]）显著增加。在三株菌株中，最低抑菌浓度为4微克/毫升。发现氟喹诺酮类药物（左氧氟沙星除外）和卡那霉素与利奈唑胺在统计学上具有显著的一致性。
相似文献
1
In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years.
Antimicrob Agents Chemother. 2008 Jun;52(6):2226-7. doi: 10.1128/AAC.00414-07. Epub 2008 Apr 7.
2
In vitro activity of linezolid against clinical isolates of Mycobacterium tuberculosis, including multidrug-resistant and extensively drug-resistant strains from Beijing, China.
Jpn J Infect Dis. 2012;65(3):240-2. doi: 10.7883/yoken.65.240.
3
First linezolid-resistant clinical isolates of Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2007 Apr;51(4):1534-6. doi: 10.1128/AAC.01113-06. Epub 2007 Jan 22.
4
In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis from Shenyang, north of China.
Indian J Med Microbiol. 2015 Feb;33 Suppl:164-5. doi: 10.4103/0255-0857.150967.
5
In vitro susceptibility of Mycobacterium tuberculosis clinical isolates to garenoxacin and DA-7867.
Antimicrob Agents Chemother. 2005 Oct;49(10):4351-3. doi: 10.1128/AAC.49.10.4351-4353.2005.
6
In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs.
Antimicrob Agents Chemother. 2003 Jan;47(1):416-7. doi: 10.1128/AAC.47.1.416-417.2003.
7
[Effect of linezolid in combination with isoniazid and rifampicin against multidrug resistant Mycobacterium tuberculosis clinical isolates].
Mikrobiyol Bul. 2009 Apr;43(2):293-7.
8
Susceptibility testing of extensively drug-resistant and pre-extensively drug-resistant Mycobacterium tuberculosis against levofloxacin, linezolid, and amoxicillin-clavulanate.
Antimicrob Agents Chemother. 2013 Jun;57(6):2522-5. doi: 10.1128/AAC.02020-12. Epub 2013 Mar 18.
9
In vitro activity of linezolid against Mycobacterium tuberculosis strains isoalted from Western Turkey.
Jpn J Infect Dis. 2009 Sep;62(5):384-5.
10
Second-line drug susceptibilities of multidrug-resistant tuberculosis strains isolated in Thailand: an update.
Int J Tuberc Lung Dis. 2014 Aug;18(8):961-3. doi: 10.5588/ijtld.13.0197.
引用本文的文献
1
The antimicrobial activity of linezolid against unconventional pathogens.
PeerJ. 2025 Feb 12;13:e18825. doi: 10.7717/peerj.18825. eCollection 2025.
2
Fluoroquinolone-resistant latent tuberculosis infection: A literature review and case series of 5 patients treated with linezolid monotherapy.
J Clin Tuberc Other Mycobact Dis. 2023 May 18;32:100376. doi: 10.1016/j.jctube.2023.100376. eCollection 2023 Aug.
3
Designing molecular diagnostics for current tuberculosis drug regimens.
Emerg Microbes Infect. 2023 Dec;12(1):2178243. doi: 10.1080/22221751.2023.2178243.
4
Linezolid resistance in multidrug-resistant mycobacterium tuberculosis: A systematic review and meta-analysis.
Front Pharmacol. 2022 Aug 30;13:955050. doi: 10.3389/fphar.2022.955050. eCollection 2022.
5
Clinical features associated with linezolid resistance among multidrug resistant tuberculosis patients at a tertiary care hospital in Mumbai, India.
J Clin Tuberc Other Mycobact Dis. 2020 Jul 24;20:100175. doi: 10.1016/j.jctube.2020.100175. eCollection 2020 Aug.
6
Linezolid resistance in patients with drug-resistant TB and treatment failure in South Africa.
J Antimicrob Chemother. 2019 Aug 1;74(8):2377-2384. doi: 10.1093/jac/dkz206.
7
Linezolid for drug-resistant pulmonary tuberculosis.
Cochrane Database Syst Rev. 2019 Mar 20;3(3):CD012836. doi: 10.1002/14651858.CD012836.pub2.
8
Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.
Ann Lab Med. 2018 Nov;38(6):563-568. doi: 10.3343/alm.2018.38.6.563.
9
Drug Susceptibility of Bedaquiline, Delamanid, Linezolid, Clofazimine, Moxifloxacin, and Gatifloxacin against Extensively Drug-Resistant Tuberculosis in Beijing, China.
Antimicrob Agents Chemother. 2017 Sep 22;61(10). doi: 10.1128/AAC.00900-17. Print 2017 Oct.
10
Mycobacterium tuberculosis Mutations Associated with Reduced Susceptibility to Linezolid.
Antimicrob Agents Chemother. 2016 Mar 25;60(4):2542-4. doi: 10.1128/AAC.02941-15. Print 2016 Apr.
本文引用的文献
1
Importance of the efflux pump systems in the resistance of Mycobacterium tuberculosis to fluoroquinolones and linezolid.
Chemotherapy. 2007;53(6):397-401. doi: 10.1159/000109769. Epub 2007 Oct 12.
2
First linezolid-resistant clinical isolates of Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2007 Apr;51(4):1534-6. doi: 10.1128/AAC.01113-06. Epub 2007 Jan 22.
3
In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans.
Antimicrob Agents Chemother. 2006 Jun;50(6):1921-6. doi: 10.1128/AAC.00052-06.
4
Mycobacterium tuberculosis in Taiwan.
J Infect. 2006 Feb;52(2):77-85. doi: 10.1016/j.jinf.2005.08.008. Epub 2005 Oct 10.
5
Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995-2003.
J Antimicrob Chemother. 2005 Dec;56(6):1058-62. doi: 10.1093/jac/dki353. Epub 2005 Oct 4.
6
Linezolid: the first oxazolidinone antimicrobial.
Ann Intern Med. 2003 Jan 21;138(2):135-42. doi: 10.7326/0003-4819-138-2-200301210-00015.
7
In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs.
Antimicrob Agents Chemother. 2003 Jan;47(1):416-7. doi: 10.1128/AAC.47.1.416-417.2003.
8
In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis.
Int J Antimicrob Agents. 2002 Dec;20(6):464-7. doi: 10.1016/s0924-8579(02)00239-x.
Zotero 插件